Immune response to SARS-CoV-2 vaccination among renal replacement therapy patients with CKD: a single-center study

Clin Exp Nephrol. 2022 Mar;26(3):305-307. doi: 10.1007/s10157-021-02156-y. Epub 2021 Nov 8.

Authors

Masatoshi Matsunami¹, Tomo Suzuki², Toshiki Terao³, Hiroshi Kuji⁴, Kosei Matsue³

Affiliations

¹ Department of Nephrology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan. matsunami.masatoshi@kameda.jp.
² Department of Nephrology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
³ Department of Internal Medicine, Division of Hematology/Oncology, Kameda Medical Center, Chiba, Japan.
⁴ Department of Urology, Kameda Medical Center, Chiba, Japan.

No abstract available

Keywords: COVID-19; Hemodialysis; Kidney transplantation; Peritoneal dialysis; SARS-CoV-2; Vaccine.

Publication types

Comparative Study
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Viral / blood*
BNT162 Vaccine / administration & dosage*
BNT162 Vaccine / immunology
Female
Humans
Immunocompromised Host
Immunogenicity, Vaccine*
Immunosuppressive Agents / adverse effects
Japan
Kidney Transplantation* / adverse effects
Male
Middle Aged
Peritoneal Dialysis
Renal Dialysis* / adverse effects
Renal Insufficiency, Chronic / diagnosis
Renal Insufficiency, Chronic / immunology
Renal Insufficiency, Chronic / therapy*
Retrospective Studies
SARS-CoV-2 / immunology*
Time Factors
Treatment Outcome
Vaccination
Vaccine Efficacy*

Substances

Antibodies, Viral
Immunosuppressive Agents
BNT162 Vaccine